Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to BNF eNews
BNF BNF for Children Medicines Complete
August 2018 Share this issue Facebook LinkedIn Twitter
 
I Welcome
Welcome to the August BNF eNewsletter.
One new drug monograph has been added to the BNF, dolutegravir with rilpivirine, and two to the BNFC in the last month, icatibant and paricalcitol.

This issue includes dose changes for canakinumab, ceritinib, ciclosporin, collagenase, ferric maltol, haloperidol decanoate, mometasone furoate, and vancomycin. We also have updated guidance on age-related macular degeneration, cardiovascular disease risk assessment and prevention, diabetic complications, dyslipidaemias: familial hypercholesterolaemia, glaucoma and ocular hypertension, and oropharyngeal infections: sore throat (acute). We have included MHRA advice on Xgeva® (denosumab) for giant cell tumour of bone and the risk of clinically significant hypercalcaemia following discontinuation, as well as for advanced malignancies involving bone: reports of new primary malignancies more frequently compared to zoledronate, and advice on Lynparza® (olaparib) and the risk of medication errors with the new pharmaceutical form. You will also find NICE technology appraisals for brentuximab vedotin for treating CD30-positive Hodgkin lymphoma, guselkumab for treating moderate to severe plaque psoriasis, and midostaurin for untreated acute myeloid leukaemia.
Kind regards,
BNF Team
I In this issue
FIP World Congress 2018 More >  
Significant changes More >  
News More >  
How to purchase BNF More >  
Drug safety update More >  
Feedback More >  
I FIP World Congress 2018
2 - 6 September 2018, Glasgow
This years' 2018 FIP congress will take place in Glasgow, Scotland, bringing together pharmacy practitioners and pharmaceutical scientists from around the world to consider ways of extending the role of pharmacists so that they play a full part in ensuring patients, and health systems, achieve full benefit from the medicines people take. The 'one-size-fits-all' approach is clearly failing many patients around the globe for the pharmacological treatment of disease. Pharmacists and pharmaceutical scientists are uniquely trained and qualified health care professionals capable of personalising therapy for improving patient outcomes.
FIP World Congress 2018
Will you be attending this year? Why not visit us at Stand No 26 where you will learn more about the new MedicinesComplete platform and Martindale's Adverse Drug Reactions checker, upcoming content from the clinical writers of the BNF and Stockley's.
What is Martindale’s ADR checker?
ADR Martindale's ADR checker provides comprehensive yet concise, clinically-useful information on adverse drug reactions to support healthcare professionals when managing patients with such reactions. Answers to adverse reaction queries can be found quickly and easily, and the format tailored to individual needs.
I Significant changes
This month's changes to the clinical content of these publications are described in three parts:

BNF and BNFC update should be read by all users
BNF update should be read by all users of the BNF
BNFC update should be read by all users of the BNF for Children
BNF 72 - BNFC 2016-2017
BNF Update
Dolutegravir with rilpivirine: new drug monograph
For further information, see dolutegravir with rilpivirine.
Denosumab (Xgeva®) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation (MHRA advice)
For further information, see denosumab.
Denosumab (Xgeva®) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronate (MHRA advice)
For further information, see denosumab.
Age-related macular degeneration: updated guidance on management
For further information, see age-related macular degeneration.
Cardiovascular disease risk assessment and prevention: updated guidance
For further information, see cardiovascular disease risk assessment and prevention.
Glaucoma and ocular hypertension: updated guidance on management
For further information, see glaucoma and ocular hypertension.
Dose changes
Ceritinib [dose and directions for administration]
For further information, see ceritinib.
Ciclosporin [indication and dose for rheumatoid arthritis updated]
For further information, see ciclosporin.
Collagenase [dose statement for Dupuytren's contracture updated]
For further information, see collagenase.
Ferric maltol [indication extension]
For further information, see ferric maltol.
NICE technology appraisal update:
NICE technology appraisals that have been added to the BNF this month include:
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
Guselkumab for treating moderate to severe plaque psoriasis
Midostaurin for untreated acute myeloid leukaemia
Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Other changes
To review other changes in BNF, click on changes.
BNF for Children Update
Icatibant: new drug monograph
For further information, see icatibant.
Paricalcitol: new drug monograph
For further information, see paricalcitol.
Other changes
To review other changes in BNF for Children, click on changes.
BNF BNF for Children Update
Dolutegravir (Tivicay®, Triumeq®, Juluca®): signal of increased risk of neural tube defects; do not prescribe to women seeking to become pregnant; exclude pregnancy before initiation and advise use of effective contraception [MHRA advice]
For further information, see dolutegravir.
Diabetic complications: updated guidance
For further information, see diabetic complications.
Dyslipidaemias: updated guidance on familial hypercholesterolemia
For further information, see dyslipidaemias.
Oropharyngeal infections, antibacterial therapy: updated guidance on sore throat (acute)
For further information, see oropharyngeal infections, antibacterial therapy.
Vaccines: updated guidance for Meningococcal group B vaccines
For further information, see vaccines.
Dose changes
Canakinumab
For further information, see canakinumab.
Mometasone furoate [prophylaxis and treatment of seasonal allergic or perennial rhinitis-age range extended in children]
For further information, see mometasone furoate.
Vancomycin [deletion of statement recommending the use of ideal body-weight to calculate intravenous doses in obese patients]
For further information, see vancomycin.
I News
Reminder - help from CPPE with BNF 75
An interactive PDF e-learning programme from the Centre for Pharmacy Postgraduate Education (CPPE) will help you familiarise yourself with recommendations in BNF 75. It comprises 10 practical case studies that help you keep up to date with recent changes in the BNF, and can be accessed here.
BNF 74
I How to purchase BNF
Purchase Print copies
Purchase print copies
To order the March 2018 edition, visit the Pharmaceutical Press website.
More
Purchase a print subscription
Purchase a print subscription and save money
A print subscription is the best way to ensure access to the latest copy of BNF as soon as it publishes.
More
BNF online
BNF online
Outside the UK, content is available via a subscription to MedicinesComplete.
Email us
BNF eBook
BNF eBook
BNF is also available as a PDF eBook.
More
Drug Safety Update
Drug Safety Update is a monthly newsletter from
the MHRA and Commission on Human Medicine.
Please follow this link to review this month's Drug Safety Update.
I Feedback on our eNewsletter
Please let us know if there are any issues that you'd like us to address in our eNewsletters. We welcome your feedback. If you have any comments or suggestions, please let us know at marketing@rpharms.com.
Subscribe to this eNewsletter here
I Related Products
Medicines Complete BNF Pharmaceutical Press
BNF
Copyright © 2018 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved. Terms of use.
BNF for Children
Copyright © 2018 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved. Terms of use.
If you do not wish to receive such mailings in the future please click here to unsubscribe.
Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.